Becton, Dickinson and Company (NYSE:BDX) Updates FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $12.95-13.15 for the period, compared to the consensus earnings per share estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $5.67 on Friday, hitting $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The firm has a 50 day moving average of $238.45 and a two-hundred day moving average of $240.53. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32. The stock has a market cap of $67.80 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45. The company has a current ratio of 1.41, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. Becton, Dickinson and Company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.86 EPS. Equities analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Analyst Upgrades and Downgrades

Separately, Barclays increased their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an overweight rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $280.00.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.